Renal Osteodystrophy

Reviews in Endocrine and Metabolic Disorders

Volumn 2, Issue 2, 2001, Pages 187-193

  González, Esther A ^a   Martin, Kevin J ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Adynomic bone; Calcium; Chronic renal failure; Hyperparathyroidism; Renal Bone Disease

Indexed keywords

ANIMAL; HUMAN; PATHOLOGY; RENAL OSTEODYSTROPHY; REVIEW; SECONDARY HYPERPARATHYROIDISM;

ANIMALS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; RENAL OSTEODYSTROPHY;

EID: 0035320351     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010058828232     Document Type: Article

References (54)

1. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV. The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kid Int 1993;43(2):436-442.
2. Reiss E, Canterbury JM, Kanter A. Circulating parathyroid hormone concentration in chronic renal insufficiency. Arch Int Med 1969;124(4):417-422.
3. Arnaud CD. Hyperparathyroidism and renal failure. Kid Int 1973;4(2):89-95.
4. Slatopolsky E, Caglar S, Pennell JP, Taggart DD, Canterbury JM, Reiss E, Bricker NS. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Inv 1971;50(3):492-499.
5. Slatopolsky E, Caglar S, Gradowska L, Canterbury J, Reiss E, Bricker NS. On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kid Int 1972;2(3):147-151.
6. Slatopolsky E, Bricker NS. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kid Int 1973;4(2):141-145.
7. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Am J Kid Dis 1994;23(2):229-236.
8. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996;97(11):2534-2540.
9. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996;11(Suppl. 3):130-135.
10. Rutherford WE, Bordier P, Marie P, Hruska K, Harter H, Greenwalt A, et al. Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. J Clin Inv 1977;60(2):332-341.
11. Lopez-Hilker S, Galceran T, Chan YL, Rapp N, Martin KJ, Slatopolsky E. Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest 1986;78(4):1097-1102.
12. Lopez-Hilker S, Dusso AS, Rapp NS, Martin KJ, Slatopolsky E. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 1990;259(3 Pt 2):F432-F437.
13. Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia-Navarro S, Torres A, et al. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone & Min Res 1996;11(7):970-976.
14. Kilav R, Silver J, Naveh-Many T. Parathyroid hormone gene expression in hypophosphatemic rats. J Clin Inv 1995;96(1):327-333.
15. Moallem E, Kilav R, Silver J, Naveh-Many T. RNA-Protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Bio Chem 1998;273(9):5253-5259.
16. Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Inv 1995;96(4):1786-1793.
17. Yi H, Fukagawa M, Yamato H, Kumagai M, Watanabe T, Kurokawa K. Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. Nephron 1995;70(2):242-248.
18. Denda M, Finch J, Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 1996;28(4):596-602.
19. Dusso A, Naumovich L, Pavlopoulos T, Finch J, Morrissey J, Slapopolsky E. Phosphorus regulation of parathyroid cell growth in renal failure: A role for the cyclin-dependent kinase inhibitor p21. J Am Soc Nephrol 1998;9:564A.
20. Dusso A, Lu Y, Pavlopoulos T, Slatopolsky E. A role for enhanced expression of transforming growth factor alpha (TGF-α) in the mitogenic effects of high phosphorus on parathyroid cell growth. J Am Soc Nephrol 1999;10(617A).
21. Tatsumi S, Segawa H, Morita K, Haga H, Kouda T, Yamamoto H, et al. Molecular cloning and hormonal regulation of PiT-1, a sodium-dependent phosphate cotransporter from rat parathyroid glands. Endocrinology 1998;139(4):1692-1699.
22. Mason RS, Lissner D, Wilkinson M, Posen S. Vitamin D metabolites and their relationship to azotaemic osteodystrophy. Clin Endocrinol 1980;13(4):375-385.
23. Christiansen C, Christensen MS, Melsen F, Rødbro P, DeLuca HF. Mineral metabolism in chronic renal failure with special reference to serum concentrations of 1.25(OH)2D and 24.25(OH)2D. Clin Nephrol 1981;15(1):18-22.
24. Juttmann JR, Buurman CJ, De Kam E, Visser TJ, Birkenhäger JC. Serum concentrations of metabolites of vitamin D in patients with chronic renal failure (CRF). Consequences for the treatment with 1-alpha-hydroxy-derivatives. Clin Endocrinol 1981;14(3):225-236.
25. Tessitore N, Venturi A, Adami S, Roncari C, Rugiu C, Corgnati A, et al. Relationship between serum vitamin D metabolites and dietary intake of phosphate in patients with early renal failure. Min Elect Meta 1987;13(1):38-44.
26. Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997;29(4):496-502.
27. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Inv 1986;78(5):1296-1301.
28. 3 of transcription of the pre-proparathyroid hormone gene. Endocrinology 1986;119(6):2864-2866.
29. 3. J Bio Chem 1988;263(5):2203-2208.
30. Demay MB, Kiernan MS, DeLuca HF, Kronenberg HM. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxy vitamin D3. Proceedings of the National Academy of Sciences of The United States of America 1992;89(17):8097-8101.
31. Mackey SL, Heymont JL, Kronenberg HM, Demay MB. Vitamin D receptor binding to the negative human parathyroid hormone vitamin D response element does not require the retinoid x receptor. Mol Endocrinol 1996;10(3):298-305.
32. Naveh-Many T, Marx R, Keshet E, Pike JW, Silver J. Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Inv 1990;86(6):1968-1975.
33. Brown AJ, Zhong M, Finch J, Ritter C, McCracken R, Morrissey J, et al. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol 1996;270(3 Pt 2):F454-F460.
34. Kremer R, Bolivar I, Goltzman D, Hendy GN. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and protooncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 1989;125(2):935-941.
35. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Inv 1993;92(3):1436-1443.
36. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kid Int 1997;51(1):328-336.
37. Kifor O, Moore FD, Jr., Wang P, Goldstein M, Vassilev P, Kifor I, et al. Reduced immunostaining for the extracellular Ca2 + -sensing receptor in primary and uremic secondary hyperparathyroidism [see comments]. J Clin Endocrinol & Met 1996;81(4):1598-1606.
38. Brown AJ, Ritter CS, Finch JL, Slatopolsky EA. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kid Int 1999;55(4):1284-1292.
39. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Inv 1997;100(12):2977-2983.
40. Evanson JM. The response to the infusion of parathyroid extract in hypocalcaemic states. Clin Sci 1966;31(1):63-75.
41. Massry SG, Coburn JW, Lee DB, Jowsey J, Kleeman CR. Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. Annals of Int Med 1973;78(3):357-364.
42. Olgaard K, Arbelaez M, Schwartz J, Klahr S, Slatopolsky E. Abnormal skeletal response to parathyroid hormone in dogs with chronic uremia. Calc Tissue Int 1982;34(4):403-407.
43. Olgaard K, Schwartz J, Finco D, Arbelaez M, Korkor A, Martin K, et al. Extraction of parathyroid hormone and release of adenosine 3′,5′-monophosphate by isolated perfused bones obtained from dogs with acute uremia. Endocrinology 1982;111(5):1678-1682.
44. Rodriguez M, Felsenfeld AJ, Llach F. Calcemic response to parathyroid hormone in renal failure: role of calcitriol and the effect of parathyroidectomy. Kid Int 1991;40(6):1063-1068.
45. Massry SG, Stein R, Garty J, Arieff AI, Coburn JW, Norman AW, et al. Skeletal resistance to the calcemic action of parathyroid hormone in uremia: role of 1,25 (OH)2 D3. Kid Int 1976;9(6):467-474.
46. Ureña P, Mannstadt M, Hruby M, Ferreira A, Schmitt F, Silve C, et al. Parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats. Kid Int 1995;47(6):1797-1805.
47. Patel SR, Ke HQ, Vanholder R, Koenig RJ, Hsu CH. Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. J Clin Inv 1995;96(1):50-59.
48. Hsu CH, Patel S. Uremic plasma contains factors inhibiting 1 alpha-hydroxylase activity. J Am Soc Nephrol 1992;3(4):947-952.
49. Couttenye MM, D'Haese PC, Verschoren WJ, Behets GJ, Schrooten I, De Broe ME. Low bone turnover in patients with renal failure. Kid Int 1999;56(Supplement 73):S70-S76.
50. Coburn J, Salusky I. Hyperparathyroidism in Renal Failure: Clinical Features, Diagnosis and Management. In: Bilezikian J, Levine M, Marcus R, eds. The Parathyroids: Basic and Clinical Concepts. New York: Raven Press Ltd, 1994;721-745.
51. Malluche H, Monier-Faugere M. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 1994;4:1631-1642.
52. 2 (Paricalcitol) Safely and Effectively Reduces the Levels of Intact PTH in Patients on Hemodialysis. J Am Soc Nephrol 1998;10(2):1427-1432.
53. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol & Met 1992;75(1):145-150.
54. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kid Dis 1995;26(5):836-844.